2-bromo-1-(3,4-difluorophenyl)propan-1-one | 23384-75-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-1-(3,4-difluorophenyl)propan-1-one
• 英文别名: 2-Brom-3',4'-difluorpropiophenon；2-bromo-3',4'-difluoropropiophenone
• CAS: 23384-75-0
• 化学式: C₉H₇BrF₂O
• 分子量: 249.055
• InChiKey: JALLRKHRTZCDBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(3,4-difluorophenyl)propan-1-one 、 1-(3-羧苯基)-2-硫脲 在 溶剂黄146 作用下， 以60.4%的产率得到3-[(-4-phenylthiazol-2-yl)amino]benzoic acid
  参考文献：
  名称：

  一种5-烷基噻唑胺衍生物及其抗抑郁的用途

  摘要：

  本发明公开了一种具备抗抑郁活性的5‑烷基噻唑胺衍生物，其能够用于制备抗抑郁药物，拓宽了现有抗抑郁化合物的范围，可作为先导化合物继续优化。与盐酸氟西汀相比，本发明化合物具有更好的抗抑郁活性。本发明化合物制备路线简单，条件温和，易于工业化大生产。

  公开号：

  CN111909111B
• 作为产物：
  描述：

  3,4-二氟苯丙酮 在 氢溴酸 溴 作用下， 以 甲醇 为溶剂， 反应 117.0h， 以100%的产率得到2-bromo-1-(3,4-difluorophenyl)propan-1-one
  参考文献：
  名称：

  [EN] MONOAMINE REUPTAKE INHIBITORS
  [FR] INHIBITEURS DE LA RECAPTURE DES MONOAMINES

  摘要：

  该发明提供了一种能够抑制一种或多种单胺再摄取的丁丙吡胺类似化合物。这些化合物可以选择性地结合到一种或多种单胺转运体上，包括多巴胺、去甲肾上腺素和5-羟色胺的转运体。这些化合物可用于治疗对单胺再摄取抑制有响应的疾病，包括成瘾、抑郁和肥胖症。

  公开号：

  WO2010121022A1

文献信息

• Arylmorpholine, preparation and use
  申请人：Glaxo Wellcome Inc.

  公开号：US05648347A1

  公开（公告）日：1997-07-15

  A method for the treatment of depression in a human being, the method comprising administering to the human being an antidepressant effective amount of a compound of the following formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R and R.sup.1 are independently hydrogen or fluorine.

  一种用于治疗人类抑郁症的方法，该方法包括向人类投予以下化合物的抗抑郁有效量：##STR1## 或其药用可接受的盐，其中R和R.sup.1独立地是氢或氟。
• Arylmorpholine preparation and use
  申请人：Glaxo Wellcome Inc.

  公开号：US05760224A1

  公开（公告）日：1998-06-02

  Novel morpholines of formula (I) and their salts, wherein R and R1 are each either hydrogen or fluorine and R2 is hydrogen or methyl. The compounds have a variety of uses in human medicine, in particular in the treatment of mental disorders such as depression. ##STR1##

  式(I)的新型吗啡啶及其盐，其中R和R1均为氢或氟，R2为氢或甲基。这些化合物在人类医学中有多种用途，特别是在治疗抑郁等精神障碍方面。##STR1##
• MONOAMINE REUPTAKE INHIBITORS
  申请人：Carroll Frank Ivy

  公开号：US20120071560A1

  公开（公告）日：2012-03-22

  The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

  本发明提供了能够抑制一种或多种单胺再摄取的伯泊隆类似化合物。该化合物可以选择性地结合到一种或多种单胺转运体上，包括多巴胺、去甲肾上腺素和血清素。这种化合物可用于治疗对单胺再摄取抑制有反应的疾病，包括成瘾、抑郁和肥胖症。
• Monoamine reuptake inhibitors
  申请人：Research Triangle Institute

  公开号：US10919841B2

  公开（公告）日：2021-02-16

  The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

  本发明提供了能够抑制一种或多种单胺再摄取的安非他酮类似物化合物。这些化合物可选择性地与一种或多种单胺转运体结合，包括多巴胺、去甲肾上腺素和血清素的转运体。此类化合物可用于治疗对抑制单胺再摄取有反应的病症，包括成瘾、抑郁症和肥胖症。
• Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Cocaine Addiction
  作者：F. Ivy Carroll、Bruce E. Blough、Philip Abraham、Andrew C. Mills、J. Ashley Holleman、Scott A. Wolckenhauer、Ann M. Decker、Antonio Landavazo、K. Timothy McElroy、Hernán A. Navarro、Michael B. Gatch、Michael J. Forster

  DOI：10.1021/jm901189z

  日期：2009.11.12

  A series of bupropion (1a) analogues (1b-1ff) were synthesized, and their in vitro and in vivo pharmacological properties evaluated with the goal of developing a la analogue that had better properties for treating addictions. Their in vitro pharmacological properties were examined by [H-3]dopamine ([H-3]DA), [H-3]serotonin ([H-3](HT)-H-5), and [H-3]norepinephrine ([H-3]NE) uptake inhibition studies, and by binding studies at the dopamine, serotonin, and norepinephrine transporters using [I-125]RTI-55 in cloned transporters. Several analogues showed increased [H-3]DA uptake inhibition with reduced or little change in [H-3](HT)-H-5 and [H-3]NE uptake inhibition relative to bupropion. Thirty-five analogues were evaluated in a 1 h locomotor activity observation test and 32 in an 8 h locomotor activity observation test and compared to the locomotor activity of cocaine. Twenty-four analogues were evaluated for generalization to cocaine drug discrimination after i.p. administration, and twelve analogues were tested in a tithe course cocaine discrimination study using oral administration. 2-(N-Cyclopropylamino)-3-chloropropiophenone (1x) had the most favorable in vitro efficacy and in vivo pharmacological profile for an indirect dopamine agonist pharmacotherapy for treating cocaine, methamphetamine, nicotine, and other drugs of abuse addiction.